CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 95 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,815,121 | +97.8% | 61,033 | +19.8% | 0.00% | +200.0% |
| Q2 2023 | $917,867 | +8.5% | 50,936 | -3.3% | 0.00% | 0.0% |
| Q1 2023 | $845,655 | -13.9% | 52,656 | -1.9% | 0.00% | -50.0% |
| Q4 2022 | $982,307 | -5.6% | 53,678 | +1.3% | 0.00% | 0.0% |
| Q3 2022 | $1,041,000 | +2.8% | 53,010 | -2.4% | 0.00% | 0.0% |
| Q2 2022 | $1,013,000 | -4.6% | 54,338 | +12.3% | 0.00% | +100.0% |
| Q1 2022 | $1,062,000 | -28.6% | 48,377 | -7.7% | 0.00% | -50.0% |
| Q4 2021 | $1,488,000 | +82.8% | 52,392 | +35.6% | 0.00% | +100.0% |
| Q3 2021 | $814,000 | -14.2% | 38,650 | -23.2% | 0.00% | 0.0% |
| Q2 2021 | $949,000 | +52.3% | 50,354 | +23.4% | 0.00% | 0.0% |
| Q1 2021 | $623,000 | +8.2% | 40,798 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $576,000 | -9.9% | 40,798 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $639,000 | -10.6% | 40,798 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $715,000 | +182.6% | 40,798 | +137.2% | 0.00% | 0.0% |
| Q1 2020 | $253,000 | -40.7% | 17,197 | +1.2% | 0.00% | 0.0% |
| Q4 2019 | $427,000 | +66.8% | 17,000 | 0.0% | 0.00% | – |
| Q3 2019 | $256,000 | -39.8% | 17,000 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $425,000 | +40.3% | 17,000 | +27.7% | 0.00% | 0.0% |
| Q1 2019 | $303,000 | -7.6% | 13,309 | +21.7% | 0.00% | 0.0% |
| Q4 2018 | $328,000 | +8.6% | 10,932 | +3.9% | 0.00% | 0.0% |
| Q3 2018 | $302,000 | – | 10,526 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |